Approvals and designations made by the U.S. Food and Drug Administration for the week ended Oct. 11.
* Eli Lilly and Co.'s Reyvow as an acute therapy for migraine with or without aura in adults.
* Novartis AG's Beovu for wet age-related macular degeneration.
* Pfenex Inc.'s PF708, a biosimilar of Eli Lilly's drug Forteo, for osteoporosis in certain patients at high risk of fracture.
* Clinuvel Pharmaceuticals Ltd.'s Scenesse to increase pain-free light exposure in adults who have a history of damage to skin resulting from erythropoietic protoporphyria.
* OraSure Technologies Inc.'s OraQuick Ebola Rapid Antigen as the first rapid diagnostic test for Ebola virus disease.
FDA headquarters in Silver Spring, Md.
* Mereo BioPharma Group PLC's navicixizumab for high-grade ovarian, primary peritoneal or fallopian tube cancer in patients who have received at least three prior therapies and/or before Roche Holding AG's Avastin.
Other designations: orphan drug
* Matinas BioPharma Holdings Inc.'s MAT2203 for cryptococcosis.
* Neuren Pharmaceuticals Ltd.'s NNZ-2591 for Angelman syndrome.